Cost of clinical events in health economic evaluations in Germany: a systematic review

Cost Effectiveness and Resource Allocation

Volumn 10, Issue , 2012, Pages

  Scheuringer, Monika ^a   Sahakyan, Narine ^b,c,d   Krobot, Karl J ^a,d   Ulrich, Volker ^e  

^a MSD Sharp and Dohme GmbH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^d UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^e UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

Costs; Diabetes mellitus; Germany; Health economics

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; EPROSARTAN; EXENDIN 4; INSULIN DETEMIR; ORAL ANTIDIABETIC AGENT; PARICALCITOL; PIOGLITAZONE; RAPAMYCIN; VARENICLINE;

ACUTE HEART INFARCTION; ANGINA PECTORIS; BLINDNESS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DIABETES MELLITUS; DIABETIC FOOT; ECONOMIC EVALUATION; FOLLOW UP; GERMANY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERPARATHYROIDISM; KIDNEY FAILURE; MACROALBUMINURIA; MICROALBUMINURIA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY; REVIEW; SYSTEMATIC REVIEW;

EID: 84861628743     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-10-7     Document Type: Review

References (35)

1. Working Paper: Cost Estimation. [http://www.iqwig.de/cost-benefit-assessment.736.en.html].
2. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee Including Major Submissions Involving Economic Analyses. Appendix L: Estimating the Present Value of Costs and Health Outcomes. Australian Government Department of Health and Ageing: Canberra, Australia;. Department of Health and Aging 2002,
3. Jacobs P, Roos NP. Standard cost lists for healthcare in Canada. Issues in validity and inter-provincial consolidation. PharmacoEconomics 1999, 15:551-560. 10.2165/00019053-199915060-00003, 10538328.
4. A guidance document for the cost process. Version 1.0. [http://www.cadth.ca/media/pdf/costing_e.pdf].
5. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. PharmacoEconomics 2002, 20:443-454. 10.2165/00019053-200220070-00002, 12093300.
6. Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B. Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation [in German]. Gesundheitswesen 2005, 67:736-746. 10.1055/s-2005-858698, 16235143.
7. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W264.
8. Annemans L, Lamotte M, Kubin M, Evers T, Verheugt FW. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. Int J Clin Pract 2006, 60:1129-1137. 10.1111/j.1742-1241.2006.01089.x, 16939558.
9. Berg J, Lindgren P, Spiesser J, Parry D, Jönsson B. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Clin Ther 2007, 29:1184-1202. 10.1016/j.clinthera.2007.06.020, 17692733.
10. Berg J, Fidan D, Lindgren P. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Curr Med Res Opin 2008, 24:2089-2101. 10.1185/03007990802222261, 18547464.
11. Berger K, Hessel F, Kreuzer J, Smala A, Diener HC. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin 2008, 24:267-274.
12. Brüggenjürgen B, Lindgren P, Ehlken B, Rupprecht HJ, Willich SN. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. Eur J Health Econ 2007, 8:51-57. 10.1007/s10198-006-0006-5, 17186199.
13. Claes C, Mittendorf T, Grond M, Graf von der Schulenburg J-M. Incremental cost-effectiveness of aspirin + dipyridamole in the secondary prevention of ischemic, non-cardioembolic stroke. Med Klin 2008, 103:778-787.
14. Gandjour A, Stock S. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 2007, 83:257-267. 10.1016/j.healthpol.2007.01.003, 17335933.
15. Jürgensen JS, Arns W, Haß B. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach. Eur J Health Econ 2009, 11:15-25.
16. Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. PharmacoEconomics 2006, 24:155-169. 10.2165/00019053-200624020-00005, 16460136.
17. Lamotte M, Annemans L, Kawalec P, Zoellner Y. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. PharmacoEconomics 2006, 24:783-795. 10.2165/00019053-200624080-00005, 16898848.
18. Liebl A, Lüddeke H-J, Kotowa W, Maclaine G, Evers T. Cost-effectiveness for acarbose therapy of patients with impaired glucose intolerance [in German]. Gesundh okon Qual manag 2006, 11:105-111.
19. Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obes Metab 2009, 11:1068-1079. 10.1111/j.1463-1326.2009.01099.x, 19732121.
20. Neeser K, Erny-Albrecht K, Völler H, Weber C. Anticoagulation with oral vitamin K antagonists in high-risk patients: clinical and economic benefits of adequate prevention. J Kardiol 2006, 13:313-320.
21. Rasch A, Greiner W. Health economic model of smoking cessation with varenicline [in German]. Suchtmed 2009, 11:47-55.
22. Rosery H, Bergemann R, Marx SE, Boehnke A, Melnick J, Sterz R, Williams L. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Investig 2006, 26:629-638. 10.2165/00044011-200626110-00002, 17163297.
23. Roze S, Valentine WJ, Evers T, Palmer AJ. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Curr Med Res Opin 2006, 22:1415-1424. 10.1185/030079906X115531, 16834840.
24. Schaufler TM. Cost-effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany [in German]. Gesundh okon Qual manag 2009, 14:71-75.
25. Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff Resour Alloc 2009, 7:9. 10.1186/1478-7547-7-9, 2688482, 19416529.
26. Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe-the HEALTH model. Value Health 2009, 12:857-871. 10.1111/j.1524-4733.2009.00507.x, 19508663.
27. Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv Ther 2008, 25:567-584. 10.1007/s12325-008-0069-z, 18568451.
28. Weber C, Neeser K, Schneider B, Lodwig V. Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessment. J Diabetes Sci Technol 2007, 1:676-684. 2769665, 19885135.
29. Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, Palmer AJ. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005, 21:1617-1629. 10.1185/030079905X65349, 16238902.
30. Hutter F, Antonanzas F. Economic evaluations in the EURONHEED: a comparative analysis. PharmacoEconomics 2009, 27:561-570. 10.2165/11310060-000000000-00000, 19663527.
31. NHS Reference Costs 2008-2009. UK Department of Health London 2010,
32. Guide to the methods of technology appraisal. [http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf].
33. Unit costs of health and social care. 2009, [http://www.pssru.ac.uk/pdf/uc/uc2009/uc2009.pdf].
34. Ridyard CH, Hughes DA. Methods for the collection of resource use data within clinical trials: A systematic review of studies funded by the UK Health Technology Assessment Program. Value Health 2010, 13:867-872. 10.1111/j.1524-4733.2010.00788.x, 20946187.
35. Scheuringer M, Krobot KJ. Development of cost catalogs for cost-effectiveness analyses in Gemany: results of a feasibility study. Value Health 2009, 12:A389.